CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Keyphrases

• Cardiovascular Outcomes 100%
• Cardiovascular Outcome Trials 100%
• Kidney Outcomes 100%
• Metabolic Outcomes 100%
• Obesity 66%
• Diabetes 66%
• Chronic Kidney Disease 66%
• Comorbidity 66%
• Heart Failure with Preserved Ejection Fraction (HFpEF) 66%
• Nonalcoholic Steatohepatitis 33%
• Chronic Disease 33%
• Dementia 33%
• Potential Treatments 33%
• Nephrologists 33%
• Clinical Trials 33%
• Diabetes Management 33%
• Heart Failure 33%
• Patient-reported Outcomes 33%
• Cancer Treatment 33%
• Cardiologists 33%
• Type 1 Diabetes Mellitus (T1DM) 33%
• Risk Reduction 33%
• Ethnic Groups 33%
• Major Adverse Cardiovascular Events 33%
• Primary Care Physicians 33%
• Cardiovascular Risk Management 33%
• Treatment Efficacy 33%
• Outcome Trials 33%
• Progress Management 33%
• Obesity Treatment 33%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 33%
• Racial Groups 33%
• Bempedoic Acid 33%
• Type I Diabetes 33%
• Continuous Glucose Monitoring 33%
• Communication Strategies 33%
• Guideline Update 33%
• Glucagon-like peptide-1 (GLP-1) 33%
• Dapagliflozin 33%
• Online Discussion 33%
• Monitoring Technology 33%
• Diabetologist 33%
• Metabolic Dysfunction-associated Steatohepatitis 33%
• Innovative Approaches 33%
• Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs) 33%
• Physician-patient Communication 33%
• Semaglutide 33%
• Endocrinologists 33%
• Nonsteroidal Mineralocorticoid Receptor Antagonist 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Kidney Failure 100%
• Heart Failure with Preserved Ejection Fraction 100%
• Cardiovascular Disease 100%
• Comorbidity 100%
• Malignant Neoplasm 50%
• Congestive Heart Failure 50%
• Clinical Trial 50%
• Nonalcoholic Fatty Liver 50%
• Glucagon Like Peptide 1 Receptor Agonist 50%
• Glucagon-Like Peptide-1 50%
• Chronic Disease 50%
• Semaglutide 50%
• Sodium Glucose Cotransporter 2 Inhibitor 50%
• Insulin Dependent Diabetes Mellitus 50%
• Gastric Inhibitory Polypeptide 50%
• Bempedoic Acid 50%
• Dapagliflozin 50%
• Mineralocorticoid Antagonist 50%
• Metabolic Dysfunction-Associated Steatohepatitis 50%
• Side Effect 50%
• Glucose 50%

Medicine and Dentistry

• Cardiovascular System 100%
• Diabetes 60%
• Chronic Kidney Disease 40%
• Cardiovascular Disease 40%
• Heart Failure with Preserved Ejection Fraction 40%
• Comorbidity 40%
• Nonalcoholic Fatty Liver 20%
• Malignant Neoplasm 20%
• Nephrologist 20%
• Clinical Trial 20%
• Congestive Heart Failure 20%
• Ethnic Group 20%
• Primary Health Care 20%
• Endocrinologist 20%
• Chronic Disease 20%
• Glucagon-Like Peptide-1 Agonist 20%
• Glucagon Like Peptide 1 20%
• Gastric Inhibitory Polypeptide 20%
• Sodium Glucose Cotransporter 2 Inhibitor 20%
• Mineralocorticoid Antagonist 20%
• Insulin Dependent Diabetes Mellitus 20%
• Bempedoic Acid 20%
• Racial Group 20%
• Dapagliflozin 20%
• Semaglutide 20%
• Metabolic Dysfunction-Associated Steatohepatitis 20%
• Patient-Reported Outcome 20%
• Side Effect 20%
• Glucose 20%